Results 81 to 90 of about 28,704 (262)

Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose. [PDF]

open access: yes, 2018
Background:Topical high-precision piezo-print delivery of microdoses of latanoprost achieved significant IOP reduction consistent with the eyedropper effect but with a 75% reduced exposure to drugs and preservatives.
Ianchulev, Tsontcho   +5 more
core  

Allergic Contact Dermatitis From Dorzolamide Without Cross‐Reactivity to Brinzolamide

open access: yes
Contact Dermatitis, EarlyView.
Elias Ghozli   +4 more
wiley   +1 more source

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1128-1147, May 2026.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

Neurotrophic keratitis after micropulse transscleral diode laser cyclophotocoagulation. [PDF]

open access: yes, 2019
PurposeTo report two cases of neurotrophic keratitis (NK) after micropulse transscleral cyclophotocoagulation (MP-TCP).ObservationsTwo patients with predisposing factors for decreased corneal sensation developed NK 1 month after MP-TCP. Both patients did
Han, Ying   +4 more
core   +1 more source

Electrically atomised formulations of timolol maleate for direct and on-demand ocular lens coatings [PDF]

open access: yes, 2017
The file attached to this record is the author's final peer reviewed version.
Ahmad, Zeeshan   +6 more
core   +2 more sources

Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.

open access: yesAmerican journal of ophthalmology-glaucoma, 2016
PURPOSE To compare the intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) 0.024% with timolol maleate 0.5% in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
F. Medeiros   +5 more
semanticscholar   +1 more source

Drug‐Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database

open access: yesArthritis &Rheumatology, Volume 78, Issue 4, Page 985-992, April 2026.
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Alex Hlavaty   +4 more
wiley   +1 more source

Timolol maleate 0.5% versus timolol maleate in gel forming solution 0.5% (timolol GFS) in open angle glaucoma in India. Preliminary safety and efficacy study

open access: yesIndian Journal of Ophthalmology, 2002
Purpose: To compare the efficacy and safety profile of Timolol maleate 0.5% versus Timolol gel forming solution (GFS) 0.5% in open angle glaucoma in Indian eyes.Methods: In a prospective crossover study 52 patients of open angle glaucoma ...
Kumar Harsh   +3 more
doaj  

Sex‐specific elevated incidence of glaucoma associated with topiramate versus valproate or lamotrigine in epilepsy, not migraine: A population‐based cohort study

open access: yesEpilepsia, Volume 67, Issue 4, Page 1690-1702, April 2026.
Abstract Objective Topiramate has been linked to increased glaucoma risk, potentially through mechanisms involving ocular fluid shifts. However, comparative risks vs other antiseizure medications (ASMs) and variation by sex or indication remain uncertain.
Cuiling Wei   +10 more
wiley   +1 more source

Hepatotoxicity Associated with Labetalol Use: A Case Report with Systematic Review and Disproportionality Analysis Using FAERS

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 4, April 2026.
Abstract Labetalol is widely prescribed as a first‐line antihypertensive in pregnancy; however, rare but potentially severe idiosyncratic hepatotoxicity has been reported, with a disproportionately strong reporting signal for liver injury relative to other β‐blockers.
Emma D. Hendriksen   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy